Three-Drug attack on rare blood cancer tested in new trial
NCT ID NCT07261163
Summary
This study is testing a combination of three drugs (obinutuzumab, zanubrutinib, and lenalidomide) as the first treatment for people newly diagnosed with mantle cell lymphoma, a type of blood cancer. It will enroll 37 adults who have not had any prior cancer treatment. The main goal is to see if this approach is feasible and effective at putting the cancer into remission, with some patients receiving additional CAR-T cell therapy and long-term maintenance drugs to help keep the cancer under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.